RedHill Biopharma (RDHL) Debt Ratio (2020 - 2022)

RedHill Biopharma (RDHL) has reported Debt Ratio for 3 consecutive years, with 0.73 the latest figure, recorded in Q4 2022.

• On a quarterly basis, Debt Ratio rose 57.14% year-over-year to 0.73 in Q4 2022; TTM through Dec 2022 was 0.73, a 57.14% increase from a year earlier, with the FY2022 full-year figure at 0.73, up 57.14% from the prior year.
• Debt Ratio was 0.73 for Q4 2022 at RedHill Biopharma, roughly flat from 0.72 in the prior quarter.
• Over five years, Debt Ratio peaked at 0.73 in Q4 2022 and troughed at 0.37 in Q1 2021.
• A 3-year average of 0.51 and a median of 0.48 in 2020 frame the typical range for Debt Ratio.
• Across the five-year window, Debt Ratio plunged 31.18% in 2021 and surged 61.61% in 2022, its largest moves.
• Over 3 years, Debt Ratio stood at 0.45 in 2020, then climbed by 2.21% to 0.46 in 2021, then surged by 57.14% to 0.73 in 2022.
• The last three Debt Ratio figures came in at 0.73 (Q4 2022), 0.72 (Q3 2022), and 0.51 (Q2 2022), per Business Quant data.